Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2009

View Archived Issues

DMC recommends continuation of two phase III trials of salmon calcitonin in osteoporosis

QLT initiates phase Ib study of QLT-091001 in Leber's congenital amaurosis

Recombinant protein TAT/54R/KDEL inhibits CXCR4/CXCR12 interaction

Novel agent may shed light on formin activity in metastasis

Vitae Pharmaceuticals describes novel antidiabetic compounds

Institute for OneWorld Health claims CFTR inhibitors for the treatment of diarrhea

Solvay presents novel CB1 receptor antagonists for obesity therapy

Orexin receptor antagonists in development at GSK for the treatment of sleep disorders

Incyte identifies JAK inhibitors for cancer therapy

Can-Fite BioPharma to initiate phase II trial of CF-101 in glaucoma

Femta and Lonza sign manufacturing services agreement for FM-101 for RA

Ludwig Institute to study Pro-Pharmaceuticals' chemoprotective anticancer agent Davanat

Enrollment initiated in clinical trial of influenza vaccine in HIV-positive adults

Chelsea Therapeutics to change enrollment and primary endpoint of phase III droxidopa trial

Enrollment completed in first stage of phase II/III trial of C-Cure stem therapy for heart failure

Addex and Merck & Co. extend Parkinson's disease research collaboration

FOV-2304 prevents retinal edema and inflammation in rat model of diabetic retinopathy

PRO-131921 shows clinical activity in rituximab-relapsed/refractory indolent NHL patients

Phase II data of cediranib plus fulvestrant in metastatic breast cancer disclosed

Jazz Pharmaceuticals submits NDA to FDA for JZP-6 for the treatment of fibromyalgia

Antisoma announces results of phase II trial of AS-1411 in kidney cancer

Cubist Pharmaceuticals completes acquisition of Calixa Therapeutics

Achillion reports proof-of-concept data on ACH-1625 in hepatitis C

Auxilium reports topline phase IIb results of Xiaflex in Peyronie's disease

Taspoglutide meets primary endpoints in head-to-head phase III studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...